CDA | Evidence Driven
CDA | Evidence Driven

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details

Details

Files
Generic Name:
Apalutamide
Project Status:
Complete
Therapeutic Area:
metastatic castration-sensitive prostate cancer (mCSPC)
Manufacturer:
Janssen Inc.
Brand Name:
Erleada
Project Line:
Reimbursement Review
Project Number:
PC0200-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
60 mg
Tumour Type:
Genitourinary
Indications:
Metastatic Castration-Sensitive Prostate Cancer
Funding Request:
For the treatment of metastatic castration-sensitive prostate cancer (mCSPC)
Pre Noc Submission:
Yes
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Apalutamide (Erleada) mCSPC – pERC Final Recommendation Final Recommendation April 22, 2020 View PDF
Apalutamide (Erleada) mCSPC – Final Economic Guidance Report Guidance Reports April 22, 2020 View PDF
Apalutamide (Erleada) mCSPC – Final Clinical Guidance Report Guidance Reports April 22, 2020 View PDF
Apalutamide (Erleada) mCSPC – pERC Initial Recommendation Initial Recommendation April 2, 2020 View PDF
Apalutamide (Erleada) mCSPC – PAG Feedback on Initial Recommendation Feedback April 22, 2020 View PDF
Apalutamide (Erleada) mCSPC – Manufacturer Feedback on Initial Recommendation Feedback April 22, 2020 View PDF
Apalutamide (Erleada) mCSPC – Clinician Feedback on Initial Recommendation Feedback April 22, 2020 View PDF
Apalutamide (Erleada) mCSPC – Patient Advocacy Group COI Declarations COI Declarations April 22, 2020 View PDF
Apalutamide (Erleada) mCSPC – Clinician COI Declarations COI Declarations April 22, 2020 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : May 7, 2020